Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24530135 | 0.87 | PIN1 (0.53) | HDAC1HDAC6SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL29144589 | 0.87 | PIN1 (0.53) | HDAC1HDAC6SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL22871649 | 0.84 | YAP1 (0.61) | YAP1CCR1GAA | |
| SCHEMBL24530132 | 0.84 | CTSL (0.57) | — | |
| SCHEMBL7281178 | 0.82 | ALDH1A1 (0.53) | HDAC1HDAC6PARP1PARP3ALDH1A1 | |
| SCHEMBL7281189 | 0.82 | ALDH1A1 (0.53) | HDAC1HDAC6PARP1PARP3ALDH1A1 | |
| SCHEMBL9441281 | 0.82 | ALDH1A1 (0.53) | HDAC1HDAC6PARP1PARP3ALDH1A1 | |
| SCHEMBL4145476 | 0.82 | HDAC1 (0.63) | HDAC1HDAC6PARP1PARP3POLB | |
| SCHEMBL4145473 | 0.82 | HDAC1 (0.63) | HDAC1HDAC6PARP1PARP3POLB | |
| SCHEMBL5966500 | 0.82 | HDAC1 (0.63) | HDAC1HDAC6PARP1PARP3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263502-B1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-20240083845-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-03-14 | — | — | US | disclosed |
| EP-4263502-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022129953-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129953-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083845-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | ACE2, SARS1, ACE | YAP1 2324/4885HDAC1 1642/4885HDAC6 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.